CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Metzger Michael A Chief Executive Officer | Option exercise · Stock options (Right to buy) 10b5-1 | +7,814 | 0 | ||
| 2025-02-10 | Goldan Keith A. Chief Financial Officer | Sale | −3,777 | $15.50 | $59K | 90,746 |
| 2025-02-10 | Metzger Michael A Chief Executive Officer | Sale | −13,288 | $15.50 | $206K | 300,121 |
| 2025-02-10 | Gallagher Neil President, Head of R&D | Sale | −4,618 | $15.50 | $72K | 85,095 |
| 2025-02-05 | Gallagher Neil President, Head of R&D | Grant or award | +18,500 | 66,313 | ||
| 2025-02-05 | Gallagher Neil President, Head of R&D | Grant or award | +23,400 | 89,713 | ||
| 2025-02-05 | Gallagher Neil President, Head of R&D | Grant or award · Stock Options (Right to buy) | +110,500 | $14.65 | $1.6M | 110,500 |
| 2025-02-05 | Goldan Keith A. Chief Financial Officer | Grant or award | +18,500 | 71,123 | ||
| 2025-02-05 | Goldan Keith A. Chief Financial Officer | Grant or award | +23,400 | 94,523 | ||
| 2025-02-05 | Goldan Keith A. Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +110,500 | $14.65 | $1.6M | 110,500 |
| 2025-02-05 | Metzger Michael A Chief Executive Officer | Grant or award | +60,500 | 224,409 | ||
| 2025-02-05 | Metzger Michael A Chief Executive Officer | Grant or award | +89,000 | 313,409 | ||
| 2025-02-05 | Metzger Michael A Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +364,000 | $14.65 | $5.3M | 364,000 |
| 2025-02-05 | Podlesak Dennis Director | Grant or award | +50,000 | 191,763 | ||
| 2025-02-05 | Rizo Aleksandra Director | Grant or award | +25,000 | 25,000 | ||
| 2025-02-05 | Meury William Director | Grant or award | +25,000 | 90,000 | ||
| 2025-02-05 | Katkin Keith Director | Grant or award | +25,000 | 90,000 | ||
| 2025-02-05 | Jarrett Jennifer Director | Grant or award | +25,000 | 90,000 | ||
| 2025-02-05 | Huber Martin H. Jr. Director | Grant or award | +25,000 | 74,000 | ||
| 2025-02-05 | Legault Pierre Director | Grant or award | +25,000 | 90,000 |
Page 4 of 15 · 290 trades